At DNAe we are leading the way in rapid, near-patient sequencing testing that will revolutionize patient care for a range of unmet clinical needs. Find out more from our Co-Founder, Professor Christofer Toumazou and our CEO, Sam Reed.

DNAe is committed to consistently providing high quality products and services for its customers and meeting regulatory requirements through adherence to its established Quality Management System and a commitment to maintaining its effectiveness.

DNAe has developed a wide portfolio of patents and know-how around semiconductor technology, systems engineering and molecular biology for life science applications.

DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, today announces positive results from internal tests using its LiDia-SEQ™ sequencing technology to identify SARS-CoV-2.

DNAe’s initial focus is on developing infectious disease diagnostics, where speed and DNA sequence information can make the difference between life and death.

DNAe is a forward thinking and progressive company, that is integrating cutting-edge science, engineering and technology to develop life-saving diagnostic products.

2024年1月5日 · DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications where rapid point-of-need diagnostics are of critical need, including infectious disease and cancer testing and monitoring.

As part of its automated NGS workflow development, DNAe has developed a proprietary method to rapidly capture and enrich mutations of cancer ctDNA directly from plasma, named Specific Variant Capture (SVC).

DNAe has reinvented sequencing in order to develop a compact device operable by non-specialist users. LiDia-SEQ™ will, for the first time, bring genomic analysis into use at the point-of-need to meet urgent medical needs.

DNAe’s BSI/AMR test takes approximately 3-4 hours to complete and with regulatory clearance can deliver actionable results to the clinician at the point-of-need.